1 Recommendations


Ritlecitinib is recommended, within its marketing authorisation, as an option for treating severe alopecia areata in people 12 years and over. Ritlecitinib is only recommended if the company provides it according to the commercial arrangement.

Why the committee made these recommendations

There is no standard treatment for severe alopecia areata, and access to treatment varies widely. Hair loss can cause severe psychological distress.

Evidence from clinical trials shows that ritlecitinib is more effective than placebo at improving hair regrowth for up to 24 weeks.

The most likely cost-effectiveness estimates are within the range that NICE considers an acceptable use of NHS resources. So, ritlecitinib is recommended.

  • National Institute for Health and Care Excellence (NICE)